Prediction of paclitaxel resistance in breast cancer: Is CYP1B1*3 a new factor of influence?

Pharmacogenomics

Volumn 9, Issue 7, 2008, Pages 969-974

  Gehrmann, Mathias ^a   Schmidt, Markus ^b   Brase, Jan C ^a   Roos, Peter ^c   Hengstler, Jan G ^c  

^a SIEMENS AG   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c TU DORTMUND UNIVERSITY   (Germany)

Author keywords

Adjuvant therapy; Breast cancer; Chemotherapy; CYP1B1; Paclitaxel; Progesterone receptor; Progression free survival; Steroid receptor status

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450 1B1; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DOXORUBICIN; ESTROGEN RECEPTOR; LEUCINE; MESSENGER RNA; PACLITAXEL; PROGESTERONE RECEPTOR; VALINE; ANTINEOPLASTIC AGENT; CYP1B1 PROTEIN, HUMAN; CYTOCHROME P450;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CODON; DOSE RESPONSE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG INACTIVATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SENSITIVITY; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; NONHUMAN; PHARMACOGENETICS; PREDICTION; PROGNOSIS; RELIABILITY; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST TUMOR; DISEASE FREE SURVIVAL; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; GENETIC POLYMORPHISM; GENETICS; PATHOLOGY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PACLITAXEL; POLYMORPHISM, GENETIC;

EID: 49949097267     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.7.969     Document Type: Article

References (25)

1. Spangenberg C, Lausch EU, Trost TM et al.: ERBB2-mediated transcriptional up-regulation of the α5β1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions. Cancer Res. 66(7), 3715-3725 (2006).
2. Trost TM, Lausch EU, Fees SA et al.: Premature senescence is a primary fail-safe mechanism of ERBB2-driven tumorigenesis in breast carcinoma cells. Cancer Res. 65, 840-849 (2005).
3. Schiffer IB, Gebhard S, Heimerdinger CK et al.: Switching off her-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission. Cancer Res. 63, 7221-7231 (2003).
4. Mohrmann G, Hengstler JG, Hofmann TG et al.: SPOC1, a novel PHD-finger protein: association with residual disease and survival in ovarian cancer. Int. J. Cancer 116, 547-554 (2005).
5. Micke P, Basrai M, Faldum A et al.: Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin. Cancer Res. 9, 188-194 (2003).
6. Tanner B, Hasenclever D, Stern K et al.: ErbB-3 predicts survival in ovarian cancer. J. Clin. Oncol. 24(26), 4317-4323 (2006).
7. Sudo T, Nitta M, Saya H, Ueno NT: Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res. 64, 2502-2508 (2004).
8. Rouzier R, Rajan R, Wagner P et al.: Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc. Natl Acad. Sci. USA 102, 8315-8320 (2005).
9. Paradiso, A, Mangia A, Chiriatti A et al.: Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann. Oncol. 16(Suppl. 4), iv14-iv19 (2005).
10. Schmidt M, Bremer E, Hasenclever D et al.: Role of the progesterone receptor for paclitaxel resistance in primary breast cancer. Br. J. Cancer 96(2), 241-247 (2007).
11. Marsh S, Somlo G, Li X et al.: Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 7(5), 362-365 (2007).
12. Bailey LR, Roodi N, Dupont WID, Parl FF: Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res. 58(22), 5038-5041 (1998); erratum in: Cancer Res. 59(6), 1388 (1999).
13. Kocabas NA, Sardas S, Cholerton S, Daly AK, Karakaya AE: Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population. Arch. Taxicol. 76(11), 643-649 (2002).
14. Thier R, Brüning T, Roos PH, Bolt HM: Cytochrome P450 1B1, a new keystone in gene-environment interactions related to human head and neck cancer? Arch. Toxicol. 76(5-6), 249-256 (2002).
15. Roos PH, Bolt HM: Cytochrome P450 interactions in human cancers: new aspects considering CYP1B1. Expert Opin. Drug Metab. Toxicol. 1(2), 187-202 (2005).
16. Roos PH, Belik R, Follmann W et al.: Expression of cytochrome P450 enzymes CYP1A1, CYP1B1, CYP2E1 and CYP4B1 in cultured transitional cells from specimens of the human urinary tract and from urinary sediments. Arch. Toxicol. 80(1), 45-52 (2006).
17. Figg WD, Li H, Sissung T et al.: Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int. 99(5), 1047-1055 (2007).
18. Paracchini V, Raimondi S, Gram IT et al.: Meta- and pooled analyses of the cytochrome P-450 1B1 Val432Leu polymorphism and breast cancer: a HuGE-GSEC review. Am. J. Epidemiol. 165(2), 115-125 (2007).
19. Schmidt M, Böhm D, von Toerne C et al.: The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. (2008) (In press).
20. Long JR, Cai Q, Shu XO, Cai H, Gao YT, Zheng W: Genetic polymorphisms in estrogen-metabolizing genes and breast cancer survival. Pharmacogenet. Genomics 17(5), 331-338 (2007).
21. Haas S, Pierl C, Harth V et al.: Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas. Int. J. Cancer 119(8), 1785-1791 (2006).
22. Fisher B, Redmond C, Fisher ER, Caplan R: Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer'patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J. Clin. Oncol. 6(7), 1076-1087 (1988).
23. Monsarrat B, Alvinerie P, Wright M et al.: Hepatic metabolism and biliary excretion of taxotlin rats and humans. J. Natl Cancer Inst. Monogr. 15, 39-46 (1993).
24. McFadyen MC, McLeod HL, Jackson FC, Melvin WT, Doehmer J, Murray GI: Cytochrome P450 CYP1B1 protein expression: 2 novel mechanism of anticancer drug resistance. Biochem. Pharmacol. 62(2), 207-212 (2001).
25. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF: Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res. 60(13), 3440-3444 (2000).